Literature DB >> 1410337

Benign adrenocortical masses: diagnosis with chemical shift MR imaging.

D G Mitchell1, M Crovello, T Matteucci, R O Petersen, M M Miettinen.   

Abstract

Benign adrenocortical masses often contain lipid; metastases and pheochromocytomas do not. Standard and lipid-sensitive (chemical shift) magnetic resonance (MR) images of the adrenal glands in 31 patients with 45 adrenal masses were reviewed to determine if simple visual analysis of these images would increase diagnostic specificity. Lipid was considered present if signal intensity of the adrenal mass relative to other tissues decreased on chemical shift images relative to comparable standard images. Both myelolipomas and 26 of 27 benign cortical masses displayed a loss of signal intensity on at least one chemical shift image; all 12 metastases, the three hemorrhages, and a cyst did not. Opposed-phase images were slightly more sensitive than fat-suppressed images in depicting lipid within benign cortical masses. All masses had higher signal intensity than that of the liver on standard T2-weighted MR images. Chemical shift MR imaging can demonstrate lipid within benign adrenocortical masses and thus increase specificity, potentially obviating biopsy and aggressive follow-up.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1410337     DOI: 10.1148/radiology.185.2.1410337

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  42 in total

1.  Magnetic resonance imaging differentiation of adrenal masses at 1.5 T: T2-weighted images, chemical shift imaging, and Gd-DTPA dynamic studies.

Authors:  R Z Słapa; W Jakubowski; E Dabrowska; A Januszewicz; B Tymińska; T Feltynowski; M Lapiński; J Fijuth
Journal:  MAGMA       Date:  1996 Sep-Dec       Impact factor: 2.310

2.  The value of in-phase and opposed-phase T1-weighted breath-hold FLASH sequences for hepatic imaging.

Authors:  H Xu; D Jiang; L Yang; Y Xiong; F Yang; X Kong
Journal:  J Tongji Med Univ       Date:  2000

Review 3.  Tuberous sclerosis complex renal disease.

Authors:  Bradley P Dixon; John C Hulbert; John J Bissler
Journal:  Nephron Exp Nephrol       Date:  2010-11-11

4.  Evaluation and management of the incidental adrenal mass.

Authors:  David T Arnold; Jennifer Blumoff Reed; Kristina Burt
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

Review 5.  Minimal access adrenal surgery.

Authors:  L M Brunt
Journal:  Surg Endosc       Date:  2006-01-25       Impact factor: 4.584

Review 6.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 7.  The clinical evaluation of silent adrenal masses.

Authors:  B Ambrosi; E Passini; T Re; L Barbetta
Journal:  J Endocrinol Invest       Date:  1997-02       Impact factor: 4.256

8.  Isolated fat-containing pancreatic metastasis from hepatocellular carcinoma.

Authors:  Hideyuki Nishiofuku; Nagaaki Marugami; Toshihiro Tanaka; Hiroshi Anai; Shinsaku Maeda; Tetsuya Masada; Masato Takano; Akira Mitoro; Kimihiko Kichikawa
Journal:  Jpn J Radiol       Date:  2013-03-29       Impact factor: 2.374

9.  Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours?

Authors:  L Tessonnier; F Sebag; F F Palazzo; C Colavolpe; C De Micco; J Mancini; B Conte-Devolx; J F Henry; O Mundler; D Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

10.  Computed tomography findings in diseases of the adrenal gland.

Authors:  Ersin Ozturk; H Onur Sildiroglu; Mecit Kantarci; Selim Doganay; Fadime Güven; Mahmut Bozkurt; Guner Sonmez; C Cinar Basekim
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.